Informations générales (source: ClinicalTrials.gov)
Interventional
Phase 2
Versailles Hospital (Voir sur ClinicalTrials)
mars 2014
septembre 2016
02 mai 2026
Botulinum toxin is used in musculoskeletal therapy routinely for 15 years. This is one of
the most potent neurotoxins. It comes in 7 serotypes (A to G).Therapeutic application of
botulinum toxin are mainly based on its ability to block the neuromuscular transmission
by preventing the release of acetylcholine, creating paralysis muscle relative and
reversible.
It has been used in the treatment of cervical dystonia, migraine headaches, and an
antinociceptive effect. The analgesic effect occurred even prior to the release muscular.
Several randomized studies have been published about it. The investigators assume that
intramuscular injection of botulinum toxin is effective in the treatment of tendinopathy
rotator cuff.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CH DE VERSAILLES SITE ANDRE MIGNOT | Pujol Nicolas, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
- Signed consent
- Active social care
- Compliant patient with protocol
- Patient more than 18 years
- Positive Neer Test
Exclusion Criteria:
- Prior study exclusion period
- Protected patient
- Study refusal
- Deficient patient
- Rheumatoid arthritis, osteoarthritis, chondrocalcinosis.
- Microcrystalline arthritis.
- Active infection .
- History of hypersensitivity reaction during a previous injection of botulinum toxin
- Bilateral involvement
- Neurological deficit
- Depression
- History of shoulder surgery
- Pregnant or breast feeding women
- Systemic disease (diabeta, vascularitis)
- Known neurological disease
- Intraarticular associate disease
- Acromioclavicular associate disease
- Myasthenia
- Botulinum toxin is not recommended in combination with aminoglycosides